Improved Patient Outcomes and Financial Performance
The Value of Integrated Outsourced Services Supporting Rare Disease Pharmaceutical Companies
The $114 billion orphan drug industry is traditionally served by a multi-channel model of disparate service providers. Each claims expertise in a specific niche of services, yet therapy adherence for rare disease patients is disappointing at just over 58%. The biopharma industry, and rare disease sector specifically, face reputational concerns. From the ever increasing cost of healthcare to the fact that 74% of Americans believe drug companies put profits over patients, the traditional outsourcing model of yesterday is putting the industry’s future at risk.
Our 2017 white paper explores a new integrated outsourcing model that’s driving better adherence, supporting healthier outcomes and using data and insights to help orphan drug manufacturers continuously improve their patient program. Industry experts and patient advocates weigh in on why business process outsourcing must evolve.
“The most difficult challenge is trying to identify and understand why patients slip through the cracks,” shares one expert. “If you had just one partner with the ability to track accurate and complete data in a format that’s easy to analyze, that would be a tremendous advantage.”
The paper explores the opportunity to improve onboarding, patient support, and data collection and analysis for the benefit of not only the manufacturer, but also for the patients they serve.